Title

Applications of MOSkin dosimeters for quality assurance in gynecological HDR brachytherapy: An in-phantom feasibility study

RIS ID

111913

Publication Details

Romanyukha, A. A., Carrara, M., Tenconi, C., Mazzeo, D., Rossi, G., Borroni, M., Pignoli, E., Cerrotta, A., Cutajar, D., Petasecca, M., Lerch, M., Bucci, J. & Rosenfeld, A. B. (2016). Applications of MOSkin dosimeters for quality assurance in gynecological HDR brachytherapy: An in-phantom feasibility study. Radiation Measurements, Online First 1-6.

Abstract

In vivo dosimetry (IVD) is an excellent mode of treatment verification and detection of possible overexposures. A feasibility study was conducted to evaluate a proposed IVD procedure for gynecological HDR brachytherapy procedure quality assurance. MO. Skin dosimeters were selected due to their small size and capability of measuring steep dose gradients, such as those relevant in HDR brachytherapy procedures. Two in-phantom experiments measuring dose with MO. Skins at the position simulating the rectal wall were conducted employing a cylindrical single channel applicator and a multichannel applicator. Three MO. Skins were incorporated onto a rectal catheter, which was then attached to the applicator, separated by a small wooden plaque, simulating the vaginal to rectal wall distance and fixing catheter position. This setup was inserted into a water phantom and three treatment plans prescribing 300 cGy to 3 different targets were assigned with various dose distributions. Each treatment was administered three times, and doses measured by the MO. Skins were recorded. Doses measured by the MO. Skins were within 5% of the dose determined by the treatment planning system (TPS), ranging between 208 and 332 cGy, depending on dosimeter position on the rectal catheter. The overall average dose difference between measured and TPS values was 2.09% ± 1.15% (ranging between 0.83 and 4.27%, with measured values always higher than TPS dose), subdivided in 1.40 ± 0.37% and 2.79 ± 1.27% for single and multichannel applicator experiments, respectively. An overall dose agreement between the TPS and measured values, detector reproducibility, and practicality of the rectal catheter demonstrated the suitability of the proposed method for in vivo real time QA purposes in gynecological HDR brachytherapy.

Please refer to publisher version or contact your library.

Share

COinS
 

Link to publisher version (DOI)

http://dx.doi.org/10.1016/j.radmeas.2016.12.010